Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms.

Kelly DL, Vyas G, Richardson CM, Koola M, McMahon RP, Buchanan RW, et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophrenia Res. 2011;133(1-3):257-8. DOI: 10.1016/j.schres.2011.08.005. PubMed PMID: 21872445.

Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy

Friedman JI, Lindenmayer J-P, Alcantara F, Bowler S, Parak M, White L, et al. Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy. Neuropsychopharmacology. 2011;36(10):2150- 2150. DOI: 10.1038/npp.2011.68.

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.

Jassim G, Skrede S, Vázquez MJ, Wergedal H, Vik-Mo AO, Lunder N, et al.. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology. 2012;219(3):783-94. DOI: 10.1007/s00213-011-2397-y. PubMed PMID: 21748251; PubMed Central PMCID: PMC3259403.

The College of Psychiatric and Neurologic Pharmacists (CPNP) Announces Saklad Memorial Award and Research Award Recipients Presented at the 2011 CPNP Annual Meeting

Saklad Memorial Award

CPNP was honored to present the Saklad Memorial Award at the May 2011 CPNP Annual Meeting for the fourteenth time. This award celebrates the life and work of the late Judith J. Saklad. Dr. Saklad was a founding member of CPNP and nationally recognized as an innovator of pharmaceutical care to children and adults with serious mental disorders, developmental disabilities and mental retardation. 

The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study.

Whiskey E, Olofinjana O, Taylor D. The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study. J Psychopharmacol. 2011;25(6):842-5. DOI: 10.1177/0269881110364267. PubMed PMID: 20305043.

Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia.

Henderson DC, Freudenreich O, Borba CPC, Wang X, Copeland PM, Macklin E, et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophrenia Res. 2011;130(1-3):53-6. DOI: 10.1016/j.schres.2011.04.009. PubMed PMID: 21565464.

Current treatment strategies for clozapine-induced sialorrhea.

Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother. 2011;45(5):667-75. DOI: 10.1345/aph.1P761. PubMed PMID: 21540404.

Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.

Krakowski M, Czobor P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophrenia Res. 2011;130(1-3):27-33. DOI: 10.1016/j.schres.2011.04.005. PubMed PMID: 21549568.

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.

Muscatello MRA, Bruno A, Pandolfo G, Micò U, Bellinghieri PM, Scimeca G, et al.. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol. 2011;25(5):667-74. DOI: 10.1177/0269881110372548. PubMed PMID: 20615930.

Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine.

Mendhekar DN, Andrade C. Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine. Ann Pharmacother. 2011;45(4):545-6. DOI: 10.1345/aph.1P194. PubMed PMID: 21487079.